DOK2 Antikörper (C-Term)
Kurzübersicht für DOK2 Antikörper (C-Term) (ABIN392072)
Target
Alle DOK2 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 380-412, C-Term
-
Aufreinigung
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
-
Immunogen
- This DOK2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 380-412 amino acids from the C-terminal region of human DOK2.
-
Isotyp
- Ig Fraction
-
-
-
-
Applikationshinweise
- WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
-
Haltbarkeit
- 6 months
-
-
- DOK2
-
Andere Bezeichnung
- DOK2
-
Hintergrund
- Docking proteins interact with receptor tyrosine kinases and mediate particular biological responses using signal transduction. Dok-2 acts as a multiple docking protein downstream of receptor or non-receptor tyrosine kinases. By this mechanism it acts to negatively regulate signal transduction and cell proliferation controlled by cytokines in a feedback loop. Dok-2 is highly expressed in cells and tissues of hematopoietic origin as well as in lung. Expression of bcr/abl induces additional tyrosine phosphorylation of the Dok1 and Dok2 proteins and their association with Ras-GAP. Thus, it is suspected that DOK association regulates GAP activity toward Ras and that the Dok proteins serve as mediators of bcr-abl signaling. The role of Dok proteins in bcr-abl regulation may also be implicated in chronic myelogenous leukemia (CML), which is characterized by a Philadelphia chromosome translocation t(9,22). Such a mutation would result in a p210-bcr/abl chimeric protein-tyrosine kinase which has been found in many CML cases.
-
Molekulargewicht
- 45379
-
Gen-ID
- 9046
-
NCBI Accession
- NP_003965
-
UniProt
- O60496
Target
-